The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
Author: PAM BELLUCK
Advertisements
{
"slotId": "6845006044",
"unitType": "responsive",
"resize": "auto"
}